MARK2 and neuroblastoma: Currently, many studies with molecular targeting (anti MYCN, anaplastic lymphomakinase - ALK, phosphatidylinositol 3 kinase / serine threonine kinase inhibitors -PI3K target of rapamycin - mTOR target protein and aurora kinase) and immunotherapyare currently being developed for the treatment of high-risk NB.